PL355330A1 - Kompozycje farmaceutyczne - Google Patents

Kompozycje farmaceutyczne

Info

Publication number
PL355330A1
PL355330A1 PL00355330A PL35533000A PL355330A1 PL 355330 A1 PL355330 A1 PL 355330A1 PL 00355330 A PL00355330 A PL 00355330A PL 35533000 A PL35533000 A PL 35533000A PL 355330 A1 PL355330 A1 PL 355330A1
Authority
PL
Poland
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
PL00355330A
Other languages
English (en)
Other versions
PL199727B1 (pl
Inventor
Christopher Bourne Chapleo
Keith Mccormack
Nicolas Calvert Varey
Original Assignee
Reckitt Benckiser Healthcare (Uk) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927359.1A external-priority patent/GB9927359D0/en
Application filed by Reckitt Benckiser Healthcare (Uk) Limited filed Critical Reckitt Benckiser Healthcare (Uk) Limited
Publication of PL355330A1 publication Critical patent/PL355330A1/pl
Publication of PL199727B1 publication Critical patent/PL199727B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL355330A 1999-11-19 2000-11-17 Kompozycja przeciwbólowa buprenorfiny i zastosowanie naloksonu, naltreksonu lub nalmefenu PL199727B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9927359.1A GB9927359D0 (en) 1999-11-19 1999-11-19 Improvements in or relating to organic compositions
US17620800P 2000-01-14 2000-01-14

Publications (2)

Publication Number Publication Date
PL355330A1 true PL355330A1 (pl) 2004-04-19
PL199727B1 PL199727B1 (pl) 2008-10-31

Family

ID=26316086

Family Applications (1)

Application Number Title Priority Date Filing Date
PL355330A PL199727B1 (pl) 1999-11-19 2000-11-17 Kompozycja przeciwbólowa buprenorfiny i zastosowanie naloksonu, naltreksonu lub nalmefenu

Country Status (30)

Country Link
US (4) US6995169B2 (pl)
EP (1) EP1242087B1 (pl)
JP (1) JP4745576B2 (pl)
KR (1) KR100726699B1 (pl)
CN (1) CN100431543C (pl)
AR (1) AR031682A1 (pl)
AT (1) ATE262335T1 (pl)
AU (1) AU777259B2 (pl)
BR (1) BR0015580A (pl)
CA (1) CA2392013C (pl)
CO (1) CO5261517A1 (pl)
CZ (1) CZ303160B6 (pl)
DE (1) DE60009346T2 (pl)
DK (1) DK1242087T3 (pl)
ES (1) ES2214334T3 (pl)
GB (1) GB2356348B (pl)
HU (1) HU229565B1 (pl)
IL (2) IL149580A0 (pl)
MX (1) MXPA02004978A (pl)
NO (1) NO321965B1 (pl)
NZ (1) NZ519023A (pl)
PL (1) PL199727B1 (pl)
PT (1) PT1242087E (pl)
RO (1) RO121174B1 (pl)
RU (1) RU2255737C2 (pl)
SI (1) SI21025B (pl)
SK (1) SK286888B6 (pl)
TR (1) TR200400653T4 (pl)
TW (1) TW550070B (pl)
WO (1) WO2001035942A2 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US20150031718A1 (en) * 2001-08-06 2015-01-29 Purdue Pharma L.P. Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
ES2653568T3 (es) 2004-06-12 2018-02-07 Collegium Pharmaceutical, Inc. Formulaciones de fármacos para la prevención del abuso
PT2135603E (pt) * 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
CA2674915C (en) * 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
EP2089010A1 (en) 2006-10-24 2009-08-19 The John Hopkins University Rapid release mini-tablets provide analgesia in laboratory animals
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
US20080199407A1 (en) 2007-02-15 2008-08-21 Slater Kenneth C Drug Detoxification Protocol Using Microdosing
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene
GB2447014A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
GB2447015A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
HUE027537T2 (en) * 2007-09-03 2016-10-28 Nanotherapeutics Inc Granular preparations for the administration of poorly soluble drugs
US20090082383A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched buprenorphine
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
PL2826467T3 (pl) 2010-12-22 2018-01-31 Purdue Pharma Lp Zamknięte, zabezpieczone przed manipulowaniem formy dozowania o kontrolowanym uwalnianiu
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
ME02153B (me) 2011-09-19 2015-10-20 Orexo Ab Nove farmaceutske kompozicije, otporne na zloupotrebu, za tretman zavisnosti od opioida
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
CA2899455C (en) 2013-01-30 2021-06-08 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
DK3043777T3 (da) * 2013-09-10 2020-07-20 Fresh Cut Dev Llc Sublingual buprenorphinspray
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
CA2946698A1 (en) * 2014-04-22 2015-10-29 Otsuka Pharmaceutical Co., Ltd. Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
CA3166250A1 (en) 2020-02-05 2021-08-12 Gregory G. Plucinski Drug products for intranasal administration and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
GB8430109D0 (en) 1984-11-29 1985-01-09 Gkn Technology Ltd Securing components
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
GB2213058B (en) * 1987-12-03 1991-07-17 Reckitt & Colmann Prod Ltd Compositions comprising buprenorphine and naltrexone for treatment of opiate addicts
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US20010006967A1 (en) * 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
RU2077326C1 (ru) * 1992-12-29 1997-04-20 Ярыгин Владимир Никитич Препарат для анальгезии
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
EP1280529A2 (en) * 2000-05-05 2003-02-05 Pain Therapeutics, Inc. Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists

Also Published As

Publication number Publication date
US20060058332A1 (en) 2006-03-16
NO321965B1 (no) 2006-07-31
RU2002116361A (ru) 2004-01-27
AR031682A1 (es) 2003-10-01
CA2392013A1 (en) 2001-05-25
US20060058333A1 (en) 2006-03-16
PT1242087E (pt) 2004-06-30
AU1529701A (en) 2001-05-30
NZ519023A (en) 2004-11-26
WO2001035942A9 (en) 2002-11-28
HUP0203588A3 (en) 2005-01-28
CZ303160B6 (cs) 2012-05-09
RO121174B1 (ro) 2007-01-30
WO2001035942A2 (en) 2001-05-25
IL149580A0 (en) 2002-11-10
CN100431543C (zh) 2008-11-12
IL149580A (en) 2007-05-15
HK1055389A1 (zh) 2004-01-09
BR0015580A (pt) 2002-07-09
RU2255737C2 (ru) 2005-07-10
SI21025B (sl) 2008-04-30
TR200400653T4 (tr) 2004-04-21
NO20022330D0 (no) 2002-05-15
SK8762002A3 (en) 2002-12-03
EP1242087B1 (en) 2004-03-24
JP2003514013A (ja) 2003-04-15
NO20022330L (no) 2002-07-04
KR20020058022A (ko) 2002-07-12
US20060069113A1 (en) 2006-03-30
US6995169B2 (en) 2006-02-07
CO5261517A1 (es) 2003-03-31
MXPA02004978A (es) 2003-01-28
WO2001035942A3 (en) 2002-06-13
SK286888B6 (sk) 2009-07-06
SI21025A (sl) 2003-04-30
US20030004178A1 (en) 2003-01-02
HU229565B1 (hu) 2014-02-28
EP1242087A2 (en) 2002-09-25
JP4745576B2 (ja) 2011-08-10
ES2214334T3 (es) 2004-09-16
CN1413110A (zh) 2003-04-23
DE60009346D1 (de) 2004-04-29
US7402591B2 (en) 2008-07-22
AU777259B2 (en) 2004-10-07
ATE262335T1 (de) 2004-04-15
GB2356348A (en) 2001-05-23
GB0028088D0 (en) 2001-01-03
DE60009346T2 (de) 2005-02-10
HUP0203588A2 (hu) 2003-03-28
PL199727B1 (pl) 2008-10-31
DK1242087T3 (da) 2004-07-19
GB2356348B (en) 2002-02-06
TW550070B (en) 2003-09-01
CA2392013C (en) 2009-08-11
KR100726699B1 (ko) 2007-06-13

Similar Documents

Publication Publication Date Title
HUP0202513A3 (en) Betha-carboline pharmaceutical compositions
GB0001662D0 (en) Pharmaceutical compositions
GB0028088D0 (en) Pharmaceutical compositions
PL351387A1 (en) Pharmaceutical composition
HU9901606D0 (en) Pharmaceutical compositions
AU6219601A (en) Pharmaceutical compositions
GB9827996D0 (en) Pharmaceutical Compositions
HUP0103507A2 (hu) 2-Kinolonokat tartalmazó gyógyászati készítmények
GB9923436D0 (en) Pharmaceutical compositions
EP1166786A4 (en) MEDICAL COMPOSITIONS
AU3556400A (en) Pharmaceutical compositions
AU8576801A (en) Pharmaceutical compositions
GB9809213D0 (en) Pharmaceutical compositions
GB9904163D0 (en) Pharmaceutical compositions
AU1390002A (en) Pharmaceutical compositions
AU6460400A (en) Pharmaceutical compositions
GB9911017D0 (en) Pharmaceutical compositions
ZA9811532B (en) Pharmaceutical compositions
AU6460200A (en) Pharmaceutical compositions
GB9904911D0 (en) Pharmaceutical compositions
HRP20000530B1 (en) Pharmaceutical compositions
AU6460300A (en) Pharmaceutical compositions
AU6460100A (en) Pharmaceutical compositions
GB9902651D0 (en) Pharmaceutical compositions
IL130325A0 (en) Pharmaceutical compositions comprising allicin